REFERENCES
1. Ferreli C, Gasparini G, Parodi A, Cozzani E, Rongioletti F, Atzori L. Cutaneous manifestations of scleroderma and scleroderma-like disorders: a comprehensive review. Clin Rev Allergy Immunol. 2017;53:306-36.
2. Patnaik E, Lyons M, Tran K, Pattanaik D. Endothelial dysfunction in systemic sclerosis. Int J Mol Sci. 2023;24:14385.
3. Nilforoushzadeh MA, Heidari A, Ghane Y, et al. Efficacy and safety of platelet-rich plasma therapy in systemic sclerosis and localized scleroderma; a systematic review. Arch Dermatol Res. 2025;317:504.
4. Vasquez R, Sendejo C, Jacobe H. Morphea and other localized forms of scleroderma. Curr Opin Rheumatol. 2012;24:685-93.
5. McMahan ZH, Hummers LK. Systemic sclerosis-challenges for clinical practice. Nat Rev Rheumatol. 2013;9:90-100.
7. Florez-Pollack S, Kunzler E, Jacobe HT. Morphea: current concepts. Clin Dermatol. 2018;36:475-86.
8. Snarskaya ES, Vasileva KD. Localized scleroderma: actual insights and new biomarkers. Int J Dermatol. 2022;61:667-74.
9. Allanore Y, Assassi S. Systemic sclerosis: a multisystem disease; time to think beyond scleroderma. Arthritis Rheumatol. 2025;77:805-7.
10. Sun X, Nkennor B, Mastikhina O, Soon K, Nunes SS. Endothelium-mediated contributions to fibrosis. Semin Cell Dev Biol. 2020;101:78-86.
11. Laplante P, Sirois I, Raymond MA, et al. Caspase-3-mediated secretion of connective tissue growth factor by apoptotic endothelial cells promotes fibrosis. Cell Death Differ. 2010;17:291-303.
12. Maurer B, Distler A, Suliman YA, et al. Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis. Ann Rheum Dis. 2014;73:1880-7.
13. Manetti M, Romano E, Rosa I, et al. Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis. Ann Rheum Dis. 2017;76:924-34.
14. Pérez L, Muñoz-Durango N, Riedel CA, et al. Endothelial-to-mesenchymal transition: Cytokine-mediated pathways that determine endothelial fibrosis under inflammatory conditions. Cytokine Growth Factor Rev. 2017;33:41-54.
15. Barron L, Wynn TA. Fibrosis is regulated by Th2 and Th17 responses and by dynamic interactions between fibroblasts and macrophages. Am J Physiol Gastrointest Liver Physiol. 2011;300:G723-8.
16. Kantari-Mimoun C, Castells M, Klose R, et al. Resolution of liver fibrosis requires myeloid cell-driven sinusoidal angiogenesis. Hepatology. 2015;61:2042-55.
17. Hsu T, Nguyen-Tran HH, Trojanowska M. Active roles of dysfunctional vascular endothelium in fibrosis and cancer. J Biomed Sci. 2019;26:86.
18. Tang PM, Nikolic-Paterson DJ, Lan HY. Macrophages: versatile players in renal inflammation and fibrosis. Nat Rev Nephrol. 2019;15:144-58.
19. Baci D, Bosi A, Parisi L, et al. Innate immunity effector cells as inflammatory drivers of cardiac fibrosis. Int J Mol Sci. 2020;21:7165.
20. Matsuda M, Seki E. The liver fibrosis niche: Novel insights into the interplay between fibrosis-composing mesenchymal cells, immune cells, endothelial cells, and extracellular matrix. Food Chem Toxicol. 2020;143:111556.
21. Tsou PS, Wren JD, Amin MA, et al. Histone deacetylase 5 is overexpressed in scleroderma endothelial cells and impairs angiogenesis via repression of proangiogenic factors. Arthritis Rheumatol. 2016;68:2975-85.
22. Zhu H, Chen W, Liu D, Luo H. The role of metabolism in the pathogenesis of systemic sclerosis. Metabolism. 2019;93:44-51.
23. Coit P, Schollaert KL, Mirizio EM, Torok KS, Sawalha AH. DNA methylation patterns in juvenile systemic sclerosis and localized scleroderma. Clin Immunol. 2021;228:108756.
24. Makino T, Jinnin M, Etoh M, et al. Down-regulation of microRNA-196a in the sera and involved skin of localized scleroderma patients. Eur J Dermatol. 2014;24:470-6.
25. Wang Y, Sun J, Kahaleh B. Epigenetic down-regulation of microRNA-126 in scleroderma endothelial cells is associated with impaired responses to VEGF and defective angiogenesis. J Cell Mol Med. 2021;25:7078-88.
26. Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol. 2018;36:411-20.
27. Jin S, Guerrero-Juarez CF, Zhang L, et al. Inference and analysis of cell-cell communication using CellChat. Nat Commun. 2021;12:1088.
28. Tirosh I, Izar B, Prakadan SM, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science. 2016;352:189-96.
29. Stuart T, Butler A, Hoffman P, et al. Comprehensive integration of single-cell data. Cell. 2019;177:1888-1902.e21.
30. Satija R, Farrell JA, Gennert D, Schier AF, Regev A. Spatial reconstruction of single-cell gene expression data. Nat Biotechnol. 2015;33:495-502.
31. Trapnell C, Cacchiarelli D, Grimsby J, et al. The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. Nat Biotechnol. 2014;32:381-6.
32. Wu Y, Yang S, Ma J, et al. Spatiotemporal immune landscape of colorectal cancer liver metastasis at single-cell level. Cancer Discov. 2022;12:134-53.
33. To S, Agarwal SK. Macrophages and cadherins in fibrosis and systemic sclerosis. Curr Opin Rheumatol. 2019;31:582-8.
34. Jia H, Yue G, Li P, et al. Neutrophil extracellular traps license macrophage production of chemokines to facilitate CD8+ T cell infiltration in obstruction-induced renal fibrosis. Protein Cell. ;2025:pwaf020.
35. Huang Y, Pu W, Wang L, et al. Atypical chemokine receptor 1-positive endothelial cells mediate leucocyte infiltration and synergize with secreted frizzled-related protein 2/asporin-positive fibroblasts to promote skin fibrosis in systemic sclerosis. Br J Dermatol. 2024;191:964-78.
36. Laurent P, Lapoirie J, Leleu D, et al.; Fédération Hospitalo-Universitaire ACRONIM and the Centre National de Référence des Maladies Auto-Immunes Systémiques Rares de l’Est et du Sud-Ouest (RESO). Interleukin-1β-activated microvascular endothelial cells promote DC-SIGN-positive alternatively activated macrophages as a mechanism of skin fibrosis in systemic sclerosis. Arthritis Rheumatol. 2022;74:1013-26.
37. Jankauskas SS, Wong DWL, Bucala R, Djudjaj S, Boor P. Evolving complexity of MIF signaling. Cell Signal. 2019;57:76-88.
38. Filippou PS, Karagiannis GS, Constantinidou A. Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target. Oncogene. 2020;39:2040-54.
39. Gan C, Wang Y, Xiang Z, et al. Niclosamide-loaded nanoparticles (Ncl-NPs) reverse pulmonary fibrosis in vivo and in vitro. J Adv Res. 2023;51:109-20.
40. Sun HL, Ma QY, Bian HG, Meng XM, Jin J. Novel insight on GRP/GRPR axis in diseases. Biomed Pharmacother. 2023;161:114497.
41. Russo RC, Ryffel B. The chemokine system as a key regulator of pulmonary fibrosis: converging pathways in human idiopathic pulmonary fibrosis (IPF) and the bleomycin-induced lung fibrosis model in mice. Cells. 2024;13:2058.
42. Fu Y, Li S, Zhao Y, Zhang X, Mao X, Xu R. Integrative single-cell and spatial transcriptomics analysis reveals MDK-NCL pathway’s role in shaping the immunosuppressive environment of lung adenocarcinoma. Front Immunol. 2025;16:1546382.
43. Xu C, Chen J, Liang L, et al. Midkine promotes renal fibrosis by stabilizing C/EBPβ to facilitate endothelial-mesenchymal transition. Commun Biol. 2024;7:544.
44. Sorrelle N, Dominguez ATA, Brekken RA. From top to bottom: midkine and pleiotrophin as emerging players in immune regulation. J Leukoc Biol. 2017;102:277-86.
45. Rius Rigau A, Li YN, Matei AE, et al. Characterization of Vascular Niche in Systemic Sclerosis by Spatial Proteomics. Circ Res. 2024;134:875-91.
46. Zhang L, Zhang H, Wang TY, et al. Nuclear control of mitochondrial homeostasis and venetoclax efficacy in AML via COX4I1. Adv Sci. 2025;12:e2404620.
47. Xu M, Ma Q, Fan C, Chen X, Zhang H, Tang M. Ginsenosides Rb1 and Rg1 protect primary cultured astrocytes against oxygen-glucose deprivation/reoxygenation-induced injury via improving mitochondrial function. Int J Mol Sci. 2019;20:6086.
48. Xie T, Wang C, Jin Y, et al. CoenzymeQ10-induced activation of AMPK-YAP-OPA1 pathway alleviates atherosclerosis by improving mitochondrial function, inhibiting oxidative stress and promoting energy metabolism. Front Pharmacol. 2020;11:1034.
49. Yu L, Wei W, Lv J, Lu Y, Wang Z, Cai C. FABP4-mediated lipid metabolism promotes TNBC progression and breast cancer stem cell activity. Cancer Lett. 2024;604:217271.
50. Qiao Y, Liu L, Yin L, et al. FABP4 contributes to renal interstitial fibrosis via mediating inflammation and lipid metabolism. Cell Death Dis. 2019;10:382.
51. Wu X, Shu L, Zhang Z, et al. Adipocyte fatty acid binding protein promotes the onset and progression of liver fibrosis via mediating the crosstalk between liver sinusoidal endothelial cells and hepatic stellate cells. Adv Sci. 2021;8:e2003721.
52. Wu YW, Chang TT, Chang CC, Chen JW. Fatty-acid-binding protein 4 as a novel contributor to mononuclear cell activation and endothelial cell dysfunction in atherosclerosis. Int J Mol Sci. 2020;21:9245.
53. Elmasri H, Ghelfi E, Yu CW, et al. Endothelial cell-fatty acid binding protein 4 promotes angiogenesis: role of stem cell factor/c-kit pathway. Angiogenesis. 2012;15:457-68.
54. Guo D, Lin C, Lu Y, et al. FABP4 secreted by M1-polarized macrophages promotes synovitis and angiogenesis to exacerbate rheumatoid arthritis. Bone Res. 2022;10:45.
